Steady state- AUC for bosentan var 9% højere, og AUC for den aktive metabolit, Ro 48- 5033, var 33% højere hos patienter med let nedsat leverfunktion end hos raske voluntører.
The steady state AUC of bosentan was 9% higher and the AUC of the active metabolite, Ro 48-5033, was 33% higher in patients with mild hepatic impairment than in healthy volunteers.